Search Results for citation:"86 FR 9521"

The National Institutes of Health (NIH) is offering a new invention for licensing, aiming to quickly commercialize results from government-funded research. This invention involves a vaccine technology, developed by NIH, that uses adenovirus type 4 to stimulate an immune response against SARS-CoV-2. The vaccine offers benefits like durable immunity and ease of distribution and is available for companies to license. Interested parties can obtain further information and discuss collaboration opportunities by contacting Chris Kornak from the NIH.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced that they will hold several closed meetings this February to review and evaluate contract proposals for developing pediatric formulations of tuberculosis drugs. These meetings are held under the Federal Advisory Committee Act and are closed to the public to protect confidential information and personal privacy. The meetings will be virtual, and they are occurring on February 22 and February 24, 2021, with participation led by Scientific Review Officer Mario Cerritelli. The announcements are being made less than 15 days before the meetings due to scheduling requirements aligned with the review and funding process.